From C-sections to dialysis to cancer treatment, antibiotics are the basis of modern medicine. The more we use antibiotics, the more quickly resistance develops, and deaths as a result of resistant infections are projected to skyrocket in the coming decades. 

Yet, the market for antibiotics is broken. As of January 2020, there are 60 products currently in development of which the WHO reports very few target the most critical resistant bacteria and it will take years before a handful will reach patients. Why are investments in new antibiotics to meet the threat drying up? 

Maurizio Luongo, Chief Executive Officer, Menarini Asia-Pacific shares his views.